Phase 4 N=23 Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis
Allergic Conjunctivitis
Primary: Change From Baseline in Ocular Itching at 14 Days — 2.17; 1.82 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=345 Efficacy and Safety of an Ophthalmic Solution in Patients With Allergic Conjunctivitis
Allergic Conjunctivitis
Primary: Mean Ocular Itching at Onset of Action — 0.38; 0.47; 0.59; 1.91 units on a scale
N/A N=21 Effect of Olopatadine on Allergic Tear Mediators
Allergic Conjunctivitis
Primary: Study Examined Whether the Incubation of Human Conjunctival Epithelial Cells With Tears Pooled From Allergic Subjects (One Eye With and Other Eye Without Olopatadine…
Phase 2 N=90 AGN-229666 for the Treatment of Allergic Conjunctivitis
Allergic Conjunctivitis
Primary: Ocular Itching Score at Day 1 — 0.500; 0.319; 1.867 Score on a scale
Phase 4 N=18 Non-Pharmaceutical Treatment of Seasonal Allergic Conjunctivitis
Hypersensitivity
Primary: Symptoms — 15.3; 11.3; 13.3; 9.8 Units on a scale
Phase 3 N=130 Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis
Allergic Conjunctivitis
Primary: Ocular Itching — 0.4; 1.9; 0.4; 0.5 Units on a scale
Phase 2 N=164 Safety and Efficacy Study of AL-53817 and AL-78843 Ophthalmic Solutions for Allergic Conjunctivitis
Allergic Conjunctivitis
Primary: Mean Change From Baseline in Ocular Redness, Area Under the Curve From Time Zero to Hour 10 [AUC (0-10)] at Day 7 — -2.8; -4.7; -8.1; -4.5 hours x units on a scale
Phase 2 N=154 A Study of ADX-102 in Subjects With Allergic Conjunctivitis
Conjunctivitis, Allergic
Primary: Ocular Itching Evaluated by the Subject at 10(±1) Minutes Post the Ora Calibra® Conjunctival Allergen Challenge at Day 15. — 2.020; 2.398; 2.515 units on a scale
Phase 3 N=202 Efficacy and Safety of AL-4943A Ophthalmic Solution in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) Model
Allergic Conjunctivitis
Primary: Mean Ocular Itching at Onset of Action — 0.4; 1.9; 0.4; 0.6 Units on a scale
Phase 3 N=318 ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis
Allergic Conjunctivitis
Primary: Subject-reported Ocular Itching Score — 52.003; 60.040; 74.657 units on a scale*minutes
Phase 3 N=240 AGN-229666 Ophthalmic Solution in Japanese Patients With Allergic Conjunctivitis
Conjunctivitis, Allergic
Primary: Ocular Itching Score — 0.33; 1.48; 0.29 score on a scale
Phase 3 N=87 Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis
Allergic Conjunctivitis
Primary: Mean Ocular Itching Score Compared to Placebo Period1 — 0.4; 1.7 score — p=<0.001
Phase 3 N=130 A Long-term Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis
Allergic Conjunctivitis
Primary: Change in Ocular Itching Score by Visit — -0.6; -0.9; -1.3; -1.7 score
Phase 4 N=79 Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis
Allergic Conjunctivitis
Primary: Change in Ocular Itch Score From Baseline — -1.5; -1.5 units on a scale — p=0.532
Phase 3 N=140 AGN-229666 Ophthalmic Solution for the Treatment of Seasonal or Perennial Allergic Conjunctivitis
Conjunctivitis, Allergic
Primary: Change From Baseline In Ocular Itching Frequency Score Using a 6-point Scale — 4.4; -3.4 Scores on a Scale
Phase 4 N=13 Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients
Allergic Conjunctivitis
Primary: Patient-Assessed Ocular Itching — 2.2; 2.2; 0.5; 0.5 units on a scale
Phase 2 N=120 Study Evaluating the Efficacy and Safety of PRT-2761 for the Treatment of Acute and Chronic Allergic Conjunctivitis
Allergic Conjunctivitis
Primary: Ocular Itching at 5, 7, and 10 Minutes Post CAC on Day 1 — 2.573; 2.500; 1.217; 2.647 units on a scale
Phase 2 N=236 Mapracorat Ophthalmic Formulation in Subjects With Allergic Conjunctivitis
Conjunctivitis, Allergic
Primary: Ocular Itching — 1.71; 1.34; 2.11; 2.06 score on a scale
Phase 2 N=245 Safety and Efficacy of Bepotastine Besilate Ophthalmic Solution in Seasonal Allergic Conjunctivitis Patients
Allergic Conjunctivitis
Primary: Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) - Mean Change in Total Score — -1.18; -1.17 score on a scale
Phase 2 N=122 Effect of Different Concentrations of SPARC1102 on Allergic Conjunctivitis
Allergic Conjunctivitis
Primary: Ocular Itching — 1.27; 1.57; 1.16; 1.88 units on a scale
Phase 2 N=70 Evaluation of the Effectiveness of ST266 Ophthalmic Drops Compared to Placebo to Treat Allergic Conjunctivitis
Allergic Conjunctivitis
Primary: Ocular Itching — 0.508; 0.139; 2.485; 2.535 score on a scale — p=0.0882
Phase 3 N=188 Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis
Allergic Conjunctivitis
Primary: Ocular Itching — 1.176; 1.708; 2.426; 2.362 score on a scale
Phase 4 N=157 A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis
Conjunctivitis, Allergic
Primary: Ocular Itching Evaluated by the Subject 3 Minutes Post Challenge on Day 0 — 0.40; 0.76; 2.00 Scores on a Scale
Phase 2 N=100 A Safety and Activity Study of NS2 in Subjects With Allergic Conjunctivitis
Allergic Conjunctivitis · Seasonal Allergies
Primary: Ocular Itching Score at Day 14, 60 Minutes Into the Allergen Challenge — -1.550; -1.013 units on a scale
Phase 2 N=60 Efficacy Study to Evaluate the Effectiveness of 3 Concentrations of SAR 1118 in Allergic Conjunctivitis
Allergic Conjunctivitis
Primary: Ocular Itching at Day 7 (7 Minutes Post Conjunctival Allergen Challenge [CAC 6]) — 2.65; 2.68; 3.07; 2.88 units on a scale — p=0.3235
Phase 2 N=121 A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model
Allergic Conjunctivitis
Primary: Ocular Itching — 1.908; 1.925; 1.177; 2.758 units on a scale — p=0.0002
Phase 3 N=101 Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model
Allergic Conjunctivitis
Primary: Ocular Itching at Duration of Action (16 Hours Post-dose) — 1.91; 2.00; 1.65; 2.48 units on a scale
Phase 4 N=50 Effectiveness of Olopatadine HCl Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in Japan
Allergic Conjunctivitis
Primary: Mean Ocular Itching at 7 Minutes Post-CAC, Day 1 — 0.23; 0.37 units on a scale
Phase 2 N=47 Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular Allergies
Allergic Conjunctivitis
Primary: Ocular Itching as Measured by Self-reported Numerical Scales — -0.228; 0.010; -0.424; -0.035 score on a scale
Phase 2 N=83 Efficacy of AC-150 for the Treatment of Allergic Conjunctivitis in the Enviro-CAC™ Model
Allergic Conjunctivitis
Primary: Ocular Itching at Onset of Action (15 Minutes Post-dose) — 1.33; 0.99; 2.11; 2.90 units on a scale